Skip to main content

Upexi, Inc.

UPXI
Exchange
Nasdaq
Industry
Finance Services
SEC CIK
0001775194

No open-market purchases or sales by Upexi, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $10.2M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Upexi, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Upexi, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Upexi, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Salkind GeneDirector318,750Jul 20, 20263
Dugan LawrenceDirector216,389Jul 20, 20261
Rudick Brian BenjaminChief Strategy Officer1,238,597Jul 20, 20261
Marshall AllanChief Executive Officer6,046,261Jul 20, 20263
Norstrud Andrew JamesChief Financial Officer1,049,138Jul 20, 20262
Williams Thomas CharlesDirector100,000Jul 24, 20250

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 23, 2025 (view filing)Dec 23Same dayMarshall AllanChief Executive OfficerPPurchase+50.0K$1.80+$90.0K+1.3%4.05M after
Dec 17, 2025 (view filing)Dec 15-162 daysMarshall AllanChief Executive OfficerPPurchase+150.0K$2.07+$310.5K+3.9%4.00M after2 lots
Nov 21, 2025 (view filing)Nov 201 daySalkind GeneDirectorPPurchase+50.0K$2.55+$127.5K+29.6%218.8K after
Nov 18, 2025 (view filing)Nov 171 daySalkind GeneDirectorPPurchase+100.0K$2.65+$265.0K+21.3%569.5K after
Nov 18, 2025 (view filing)Nov 171 daySalkind GeneDirectorPPurchase+100.0K$2.81+$281.0K+145.5%168.8K after
Jul 30, 2025 (view filing)Jul 1119 daysLateSalkind GeneDirector, 10% OwnerPPurchase+20.2K$4.94+$100.0K+5.5%385.4K after
Jul 24, 2025 (view filing)Jul 15-229 daysLateDugan LawrenceDirectorPPurchase+16.0K$6.11+$97.8K+15.9%116.4K after4 lots
Jul 24, 2025 (view filing)Jul 1113 daysLateMarshall AllanChief Executive OfficerPPurchase+161.9K$4.94+$800.0K+18.3%1.05M after
Apr 25, 2025 (view filing)Apr 178 daysLateMarshall AllanChief Executive OfficerPPurchase+657.9K$2.28+$1.50M+434.5%809.3K after
Apr 25, 2025 (view filing)Mar 1244 daysLateMarshall AllanChief Executive OfficerPPurchase+125.0K$2.60+$325.0K–125.0K afterDerivative
Apr 25, 2025 (view filing)Apr 178 daysLateNorstrud Andrew JamesChief Financial OfficerPPurchase+43.9K$2.28+$100.0K+287.1%59.1K after10b5-1
Apr 25, 2025 (view filing)Apr 178 daysLateSalkind GeneDirector, 10% OwnerPPurchase+241.2K$2.28+$550.0K+194.7%365.1K after
Mar 18, 2024 (view filing)Mar 11-127 daysLateMarshall AllanCHIEF EXECUTIVE OFFICERPPurchase+77.8K$0.5753+$44.7K+2.7%2.94M after2 lots
Mar 6, 2024 (view filing)Mar 51 dayMarshall AllanCHIEF EXECUTIVE OFFICERPPurchase+103.0K$0.70+$72.1K+3.7%2.86M after
Dec 20, 2023 (view filing)Dec 14-156 daysLateMarshall AllanCHIEF EXECUTIVE OFFICERPPurchase+12.9K$0.9554+$12.3K+0.5%2.77M after2 lots
Dec 7, 2023 (view filing)Dec 7Same dayMarshall AllanCHIEF EXECUTIVE OFFICERPPurchase+90.0K$0.94+$84.6K+3.4%2.75M after
Dec 6, 2023 (view filing)Dec 4-52 daysMarshall AllanCHIEF EXECUTIVE OFFICERPPurchase+53.5K$0.7569+$40.5K+2.0%2.66M after2 lots
Nov 29, 2023 (view filing)Nov 1514 daysLateMarshall AllanCHIEF EXECUTIVE OFFICERPPurchase+375.0K$0.00$0–2.46M afterDerivative10b5-1
Jul 7, 2023 (view filing)Jun 22-2815 daysLateMarshall AllanChief Executive OfficerPPurchase+79.9K$2.36+$188.9K+3.1%2.69M after5 lots
May 23, 2023 (view filing)May 221 dayMarshall AllanCHIEF EXECUTIVE OFFICERPPurchase+22.8K$3.41+$77.7K+0.9%2.61M after
Mar 20, 2023 (view filing)Mar 15-175 daysLateMarshall AllanCHIEF EXECUTIVE OFFICERPPurchase+13.0K$4.41+$57.3K+0.5%2.59M after3 lots10b5-1
Jan 11, 2023 (view filing)Dec 14-16, 202228 daysLateMarshall AllanCHIEF EXECUTIVE OFFICERPPurchase+17.3K$3.69+$63.9K+0.7%2.58M after3 lots
Dec 13, 2022 (view filing)Dec 94 daysMarshall AllanCHIEF EXECUTIVE OFFICERPPurchase+12.0K$4.11+$49.3K+0.5%2.56M after
Dec 5, 2022 (view filing)Dec 14 daysMarshall AllanCHIEF EXECUTIVE OFFICERPPurchase+18.5K$3.96+$73.2K+0.7%2.55M after
Apr 1, 2022 (view filing)Mar 302 daysSalkind GeneDirector, 10% OwnerPPurchase+125.0K$4.00+$500.0KNew position125.0K after